Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
Интенсивный контроль уровня глюкозы в крови и сосудистые исходы у пациентов с сахарным диабетом 2-го типа
2008-06-06
SCID: 54.1/9nxczetw
Discuss with AI
glycated hemoglobinintensive glucose controlmajor microvascular eventsnephropathytype 2 diabetes
Figures from the paper
Abstract (AI)
BACKGROUND: In patients with type 2 diabetes, the effects of intensive glucose control on vascular outcomes remain uncertain. METHODS: We randomly assigned 11,140 patients with type 2 diabetes to undergo either standard glucose control or intensive glucose control, defined as the use of gliclazide (modified release) plus other drugs as required to achieve a glycated hemoglobin value of 6.5% or less. Primary end points were composites of major macrovascular events (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) and major microvascular events (new or worsening nephropathy or retinopathy), assessed both jointly and separately. RESULTS: After a median of 5 years of follow-up, the mean glycated hemoglobin level was lower in the intensive-control group (6.5%) than in the standard-control group (7.3%). Intensive control reduced the incidence of combined major macrovascular and microvascular events (18.1%, vs. 20.0% with standard control; hazard ratio, 0.90; 95% confidence interval [CI], 0.82 to 0.98; P=0.01), as well as that of major microvascular events (9.4% vs. 10.9%; hazard ratio, 0.86; 95% CI, 0.77 to 0.97; P=0.01), primarily because of a reduction in the incidence of nephropathy (4.1% vs. 5.2%; hazard ratio, 0.79; 95% CI, 0.66 to 0.93; P=0.006), with no significant effect on retinopathy (P=0.50). There were no significant effects of the type of glucose control on major macrovascular events (hazard ratio with intensive control, 0.94; 95% CI, 0.84 to 1.06; P=0.32), death from cardiovascular causes (hazard ratio with intensive control, 0.88; 95% CI, 0.74 to 1.04; P=0.12), or death from any cause (hazard ratio with intensive control, 0.93; 95% CI, 0.83 to 1.06; P=0.28). Severe hypoglycemia, although uncommon, was more common in the intensive-control group (2.7%, vs. 1.5% in the standard-control group; hazard ratio, 1.86; 95% CI, 1.42 to 2.40; P<0.001). CONCLUSIONS: A strategy of intensive glucose control, involving gliclazide (modified release) and other drugs as required, that lowered the glycated hemoglobin value to 6.5% yielded a 10% relative reduction in the combined outcome of major macrovascular and microvascular events, primarily as a consequence of a 21% relative reduction in nephropathy. (ClinicalTrials.gov number, NCT00145925.)
Key Findings
1
In 11,140 patients with type 2 diabetes, intensive glucose control achieved a lower mean glycated hemoglobin level than standard control after 5 years (6.5% vs. 7.3%).
2
Intensive control reduced combined major macrovascular and microvascular events from 20.0% to 18.1% (hazard ratio, 0.90; P=0.01).
3
Intensive glucose control did not significantly reduce major macrovascular events, cardiovascular mortality, or all-cause mortality.
4
Severe hypoglycemia was more frequent with intensive control than standard control (2.7% vs. 1.5%; hazard ratio, 1.86; P<0.001).
5
The reduction in major microvascular events was driven primarily by lower nephropathy incidence (4.1% vs. 5.2%; hazard ratio, 0.79; P=0.006), with no significant retinopathy effect.
Research Object
Patients with type 2 diabetes undergoing intensive or standard glucose control
Research Subject
The effects of intensive versus standard glucose control on major macrovascular and microvascular outcomes, mortality, and severe hypoglycemia
Publication Details
Publication Date
2008-06-06
Journal
Publisher
ISSN
Cited by
7381
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
Cited by17
2013 ESH/ESC Guidelines for the management of arterial hypertension2013
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)2012
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice2021
2016 European Guidelines on cardiovascular disease prevention in clinical practice2016
2013 ESH/ESC Guidelines for the management of arterial hypertension2013
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD2019
Standards of Medical Care in Diabetes—20132012
European guidelines on cardiovascular disease prevention in clinical practice: executive summary2007
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)2018
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach2012
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association2021
Standards of Medical Care in Diabetes—20122011
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD2013
2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)2016
Hypoglycemia in Diabetes2003
Clinical Update: Cardiovascular Disease in Diabetes Mellitus2016
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice2021